clinical trial · NCT06126952
Azelastine Allergen Chamber - Onset of Action Study
MEDA Pharma GmbH & Co. KG·phase2·completed·n = 84
Seasonal Allergic RhinitisTreatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair)Treatment B: Placebo (Azelastine 0.15% vehicle) nasal sprayTreatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
brief summary
This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Unit (EEU) followed by a single dose and a 3-day treatment at home.
started
Oct 30, 2023
primary completion
Feb 23, 2024
completion
Mar 18, 2024
last updated
Mar 20, 2024
official title
Randomized, Double-blind, Cross-over Clinical Trial to Assess Onset of Action and Efficacy of Azelastine Hydrochloride 0.15% Nasal Spray in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in an Environmental Exposure Unit in Comparison to Placebo and Mometasone Furoate/Olopatadine Hydrochloride Nasal Spray
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol